Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with this therapy, in particular heart rhythm disorders due to QT interval prolongation. We present a case of ventricular arrhythmia with no QT prolongation in a patient receiving arsenic trioxide therapy.
AuWYKwongYL.Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin 2008; 29:296–304. doi:10.1111/j.1745-7254.2008.00771.x
2.
YehETBickfordCL.Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53:2231–47. doi:10.1016/j.jacc.2009.02.050
3.
UnnikrishnanDDutcherJPVarshneyaN Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97:1514–6. doi:10.1182/blood.V97.5.1514
4.
DroletBSimardCUnusual effects of a QT-prolonging drugRoden DM.arsenictrioxide, on cardiac potassium currents. Circulation 2004; 109:26–9. doi:10.1161/01.CIR.0000109484.00668.CE
5.
O’DonnellMRAppelbaumFRCoutreSE NCCN clinical practice guideline in oncology: acute myeloid leukemia. National Comprehensive Cancer Network; 2010. Available from: http://www.cancerplan.net/Best%20Practise/aml.pdf
